
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is in a strong position to capitalize on the growing market for treatments for psychiatric diseases, particularly with their new drug ALKS 2680. The company's success in the market will depend on its ability to effectively market and sell alixorexton to a wider range of physicians. However, the potential for significant revenue from this drug, combined with other potential applications for alixorexton, give Alkermes a positive outlook for future growth and success. With a strong focus on research and development and a solid financial position, Alkermes is well-positioned to continue developing and commercializing innovative treatments for unmet medical needs in the biopharmaceutical industry.
Bears say
Alkermes is dependent on third-party providers for crucial active drug products, and has a limited track record of successful commercialization of new products. While Alkermes's lead clinical candidate ALKS 2680 may be first to market in treating NT2, its efficacy is not as strong as in treating NT1, making it less competitive in the market. Additionally, there is limited evidence supporting the use of orexin in treating ADHD, posing a risk for Alkermes's ALKS 2680 in this indication.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares